Scientific Program

Conference Series Ltd invites all the participants across the globe to attend 3rd World Conference on Breast and Cervical Cancer Abu Dhabi, UAE.

Day 2 :

Keynote Forum

Yan Gao Man

International Union for Difficult-to-treat Diseases, USA

Keynote: The most updated theory with supporting data for cancer invasion and metastasis

Time : 09:30-10:30

Conference Series BreCeCan 2018 International Conference Keynote Speaker Yan Gao Man photo

Yan Gao Man is Co-Editor-in-chief of OncoMedicine, Publisher & editor-in-chief, New Approaches combating Cancer & Aging. Editor-in-chief, Journal of CancerVice President, South Hospital of Nanjing, Nanjing, China Consultant, The Health System of the Hunan Province, China Visiting Professor, China Key Laboratory of Subhealth Intervention Technology, Changsha, China Honorable Chairman, Chemotherapy Committee of Anti-cancer Association of Shanxi province, China Visiting Professor, China National Center of Colorectal Disease (Ranked #1 in China and Asian-Pacific region) Adjunct Distinguished Scientist, Hackensack University Medical Center, NJ, USA (one of 100 best US hospitals) Founder and Chairman of Board Directors and Secretary-General, International Union for Difficult-to-treat Diseases


There are two major hypotheses that explain the mechanism of tumor progression from in situ to stromal tumor invasion. One is the proteolytic enzymes theory which is based on the overproduction of MMPs by the myoepithelial cells and surrounding tumor cells and the other theory is known as focal myoepithelial cell layer disruption (FMCLD theory). Proteolytic enzymes theory—In order to invade the stroma and metastasize, tumor cells have to cross several barriers like BM, myoepithelial cell layer, interstitial tissues, and extracellular matrices, which are composed primarily of collagen, proteoglycans, laminin, elastin, and other glycoproteins. Tumor cells overexpress and secrete proteases which are capable of degrading the components of these barriers and thus facilitate their migration. According to the proteolytic enzyme theory, the progression from the in situ to the invasive stage is believed to be triggered by the overproduction of various proteolytic enzymes by the tumor cells, such as MMPs, serine proteases and cathepsins resulting in the degradation of the BM. Focal myoepithelial cell layer disruption (FMCLD) theory—recently, a new model of tumor invasion of stroma by the epithelial cells was proposed by Yan Man. According to this model, tumor invasion is triggered by a series of events which begin when the myoepithelial cells are damaged by any genetic abnormalities, inflammation, mutations, localized trauma or other physical/chemical injuries which result in the disruption of the myoepithelial cell layer or impairs the normal replacement process. In fact, it is now known that disruption in the myoepithelial cell layer is the most distinct sign of tumor invasion in breast cancer. FMCLD theory has some advantages over proteolytic theory because it focuses on the interaction of the different types of cells present in the tumor microenvironment. Focal breakdown of myoepithelial cell layer and BM at sites of white blood cell infiltration have also been observed in DCIS. Emphasizing the necessity of changes in both in “seed” and “soil” for progression, epithelial cell clusters overlying the disrupted myoepithelial layers were different from adjacent cells within the same duct with respect to ER (estrogen receptor) status, frequency or pattern of LOH and/or MSI, and expression of tumor progression-related genes, normal stem cell and proliferation markers, and showed invasion into the stroma and blood vessel-like structures. Since tumor-stromal interactions are bi-directional, identification of the initiating events requires further study. 

  • Chemotherapy and Cancer | Molecular Oncology in Breast Cancer | Womenís Health | Cancer Vaccination | Breast and Cervical Cancer Screening | Novel Approaches to Cancer Therapeutics | Cancer Epigenomics: Beyond Genomics
Location: Abu Dhabi

Session Introduction

Femi Ogunremi

National Health Service (NHS), United Kingdom

Title: New opportunity and potential for breast cancer screening on a large scale especially in poor resource area

Time : 10:30-11:00


Femi Ogunremi is the CEO and Founder of Monitor Healthcare Ltd, multiple award-winning companies through which he has been working across West Africa with diverse stakeholders both locally and at the international front to bring innovative ideas to fight the scourge of breast cancer. He is a Medical Educator and a Fellow of various professional and academic bodies. He also takes on Medical Leadership role as a Medical Appraisal for NHS England, Medical Director and is a Responsible Officer for two organizations designated under NHS England in London area.


Breast cancer is a major killer in developing countries. Unlike in developed countries, the mortality and morbidity rates are very high. In Nigeria, only about 2 out of 10 ladies diagnosed with breast cancer will survive in 10 years. The statistic is similar in most developing countries. This is contrary to 8 out of 10 survival rate in most of the developed countries. The low survival rate is majorly associated with lack of routine national screening programs in those countries hence late presentation. As most breast cancer patients present at an advanced stage of the disease, curative treatment becomes too expensive or impossible. Presently, the available and most advocated way of screening in such low resource areas is Self-Breast Examination (SBE) however, only a few of the ladies even bother to examine themselves and for those that do, understanding the examination process and what to find is not clear. Working with partners, we have been using a simple, portable, X-ray free and cheap breast scanner that uses red light technology to screen for cancerous lumps in the breast. Published evidence are showing the sensitivity of 94 to 96% and specificity of about 87%. One major advantage of the device is that it requires no consumables to function effectively and its battery operated with the capability to screen more than 70 to 100 people in one single full charge.

Hazem Khout

Nottingham Breast Institute, United Kingdom

Title: Maximizing breast conserving options for treating breast cancer

Time : 11:30-12:00


Hazem Khout has completed his Fellowship in Breast Oncoplastic Surgery at Edinburgh Breast Unit. He is a Fellow of the Royal College of Surgeons of Edinburgh and the European Board of Breast Surgery. He is currently a Consultant Breast Oncoplastic Surgeon at the Nottingham Breast Institute and an Affiliate Member at the Nottingham Breast Cancer Research Centre. He was appointed as a Professional Clinical Advisor for Surgery in East Midlands by the Public Health of England. He has a special interest in empowering breast cancer patients in making the decision and maximizing breast oncoplastic options.


Surgery plays an essential role in the treatment of primary breast cancer. Breast Conserving Surgery (BCS) has been proven to be safe and effective in treating breast cancer when it is followed by radiotherapy to the breast. Breast-conserving surgery is also more acceptable esthetically with little morbidity compared to mastectomy. However, performing breast-conserving surgery can sometimes be challenging. Chest wall perforator flaps were introduced to overcome some of these challenges and broadening the use of B, S especially in small-breasted patients. Therapeutic mammoplasty, on the other hand, was introduced to treat breast cancer in the relatively large-breasted patients to minimize the side effects of breast radiotherapy and ensure the better cosmetic outcome. We have reviewed the oncoplastic practice in our single center and audited retrospectively the use of both chest wall flaps and therapeutic mammoplasties in broadening the indication of breast conserving surgery. The results showed an increased rate of breast conserving surgery with the better cosmetic outcome. Using chest wall perforator flaps has improved the cosmetic outcome in patients who needed re-excision. Both techniques helped surgeons in securing a satisfactory margin without compromising the esthetic outcome. In selected cases, therapeutic mammoplasty was used to treat successfully multifocal cancers with adequate margin. In summary, chest wall flaps and therapeutic mammoplasty have revolutionized the breast-conserving surgery practice. Both techniques are essential components of the oncoplastic surgery. Surgeons treating patients with breast cancer should be trained to perform chest wall perforator flaps and therapeutic mammoplasties to maximize oncoplastic options for their patients.

Mouza Mohd Al Ameri

Tawam Hospital, UAE

Title: Can we avoid ALND in limited nodal disease after SLNB?

Time : 12:00-12:30


Mouza Mohd Al Ameri has completed her MBBS from UAE University in 2001 and obtained the german board in abdominal and trauma surgery 2011 from Rotkreuz Klinikum, Oberbayern /Munich. Came back home to work as a consultant general and trauma surgeon from 2011-2013 Finished 2 years fellowship in breast oncoplastic surgery from St. Elisabeth Krankenhaus/ university of cologne in 2015. Since 2015 practicing as breast oncoplastic surgeon and since April 2018 as chief of Breast care center in Tawam hospital. Al Ain city


This is 15 minutes presentation. In this short presentation, I will highlight the significance of axillary node dissection ALND, compare between the two modalities. Current surgical standards in axillary node management. Take home message.


Shilpi Roy Narad has done her M.D (Radiation Oncology) from Kasturba Medical College, Manipal-India in 2011. She has been previously associated with Shirdi Sai Baba Cancer Hospital and Research Centre, Manipal and Fortis Hospital, Gurgaon -India. She also was last associated with B.L. Kapoor Multi-Specialty Hospital, New Delhi as Attending Consultant. And she has special experience in being part of the setting up of a new Department, making departmental protocols, active participation in treatment machine commissioning, making workflow, training staffs, etc. in Fortis Hospital, Gurgaon.


Worldwide, an estimated 10-80% of individuals have diagnosed with cancer use complementary, alternative or integrative therapies during cancer treatment. Women with breast cancer are among the highest users of such therapies and usage has been increasing. Many such alternative therapies are unproven or were studied to not have any significant benefits, rather can even be harmful. Patients appear increasingly willing to discuss the use of these remedies, especially when asked by their oncologists. In order to encourage open communication of complementary/alternative medicine use by their patients, oncologists should be knowledgeable about the most commonly used remedies. Patients should be advised to avoid questionable alternative therapies in a receptive, evidence-based atmosphere. On the other hand, complementary therapies that help manage depression, anxiety, pain, nausea, fatigue, and other symptoms should be integrated into the patient’s overall care. Evidence regarding the efficacy and safety of such therapies is reviewed and implications for oncologists are discussed.

Break: Lunch Break 13:00-14:00 @ Assymetri Restaurant

Maria Aamir is the Manager of the SEHA Cancer Registry managing the operation of cancer data flow among all SEHA business entities. She holds a degree in Medicine and pursued her Postgraduate studies in Health Informatics, Public Health and Health Research from the UK. She was the first certified professional in the Emirates of Abu Dhabi achieved CTR Certification from the North American Association of Cancer Registries (NCRA) from USA. She is also an Honorary Lecturer in New York University, Abu Dhabi and Faculty of Medicine, Al Ain, UAE teaching MPH students. Her efforts are to address and promulgate high-quality cancer care utilizing the usage of cancer data for the cancer cure and to deliver high-quality cancer care.


Majority of cancer survivors at Tawam Hospital seem to be significantly less informed about their care process upon completion of their treatment. Tawam Hospital does not have a survivorship program for Cancer patients. The main
objectives were to identify and measure the components of the transition from oncology care to primary care by providing every patient and his or her primary care provider with a treatment summary and care plan and to deliver educational programs for both patient and primary care providers about a survivor’s unique needs as well as developing a self-sustain program that can be replicated at other SEHA cancer service providers. Need Assessment Baseline Data was established with the survey comprised of basic questions to explore survivor’s major concerns. Total 11 domains were assessed based on the most prevalent concerns of survivors. Each domain was given a scoring as “1” providing 3 options as fully informed, partly informed or no information. The final results were: (1) 13% of domains about which patient had full information (2) 48% domains about which patients were partly informed and (3) 38% of domains about which patients had no information at all. Cancer patients at Tawam were found significantly less informed about the care process. The problem was rectified by implementing the survivorship care program with the SCP focus. SCP template was developed within the CERNER - accessed by both Cancer Registry and Survivorship Clinic. Need assessment survey was implemented and baseline data was collected to identify utmost needs/issues. Eligible patients were identified and the part of SCP was filled by the Registry staff to be further filled by the Survivorship clinic staff. Final SCPs were reviewed by the consultant to be signed and given to the patients. Survivorship clinic requires continuous monitoring and coordination of multidisciplinary team at Tawam Hospital including, navigation process, patient satisfaction unmet needs, regular reporting and auditing to ensure the delivery of SCPs to all eligible patients and continual education on the care process to enhance coordination of care within and outside the hospital.

Shruti M Velaskar

Tata Memorial Hospital, India

Title: Evidenced based rehabilitation following breast cancer

Time : 14:30-15:00


Shruti Velaskar is working in Occupational Therapy Department Tata Memorial Hospital, She Successfully completed research by collecting, documenting and processing data for assessment and Statistical analysis for the study on Use of Indigenous Dilators in radiation-induced vaginal stenosis. Also done further follow up with the patients for the study on Quality of Life issues for the patients (the research on the same is in progress).


Introduction & Aim: Breast is an integral part of women’s self-esteem. Diagnosis and treatment following breast cancer can impose multiple degrees of physical and psychological strain on an individual associated with chemotherapy, radiation, and/or surgery. This can result in a varying amount of common impairments along with decreased ability to engage in meaningful occupations, including maintaining one’s home, returning to work and performing prior social roles and responsibilities adequately. With the noble aim to review the current literature on the role of physical activity along with its effect on clinical practice for women living with breast cancer and to present clinical guidelines on upper extremity rehabilitation was conducted in this study.
Method: We have reviewed and implemented current literature from the last 8-10 years on breast cancer patients during treatment. Studies including meta-analysis and Cochrane database which addresses breast cancer rehabilitation related issues and its treatment were selected. The treatment modalities and types of treatments were documented and reviewed for the functional
output and the treatment were modified accordingly to get maximum functional output by using occupational therapy intervention.
Result: Majority of analysis and research indicates the importance of physical, psychological, educational interventions, shoulder dysfunction, and lymphedema. Upper limb dysfunctions are mainly addressed by the majority of meta-analysis. Breast Cancer Related Lymphedema (BCRL) is one of the major concerns for both physicians as well as patients. Early detection of BCRL can be done with modern assessment methods like perimeter and bio-impedance was suggested along with standard techniques. Treatment modalities for lymphedema were listed as early exercises, manual lymphatic drainage, compression therapy, Intermittent Pneumatic Pressure Pump (IPC). There is a lack of evidence about the effectiveness of the addition of an IPC
to the routine management of BCRL. Importance of artificial breast prosthesis was documented in one of the studies on the Indian population. However, very limited study addresses use of breast prosthesis and its implication on quality of life following breast cancer. Incidence of Chemotherapy Induced Peripheral Neuropathy (CIPN) was addressed in a few studies but there was no effective tool to measure the incidence of CIPN following chemotherapy in breast cancer. Treatment and role of rehabilitation on functional output and fine motor activities are not documented in any of this literature and they are deficient in work-related and performance related studies.
Conclusion: Current studies are lacking in presenting functional output for breast cancer patients along with its impact during treatment of rehabilitation. Hence we suggest that there is a growing need for randomized and nonrandomized studies on functional output following breast cancer and the effect of occupational therapy intervention.

Break: Networking and Refreshments Break 15:00-15:30 @ Foyer